Ashton S - Search Results

1

Assessing the activity of cediranib, a VEGFR-2/3 tyrosine kinase inhibitor, against VEGFR-1 and members of the structurally related PDGFR family.

Brave SR, Ratcliffe K, Wilson Z, James NH, Ashton S, Wainwright A, Kendrew J, Dudley P, Broadbent N, Sproat G, Taylor S, Barnes C, Silva JC, Farnsworth CL, Hennequin L, Ogilvie DJ, Jürgensmeier JM, Shibuya M, Wedge SR, Barry ST. Brave SR, et al. Among authors: ashton s. Mol Cancer Ther. 2011 May;10(5):861-73. doi: 10.1158/1535-7163.MCT-10-0976. Epub 2011 Mar 25. Mol Cancer Ther. 2011. PMID: 21441409 Free article.

2

Vascular endothelial growth factor receptors VEGFR-2 and VEGFR-3 are localized primarily to the vasculature in human primary solid cancers.

Smith NR, Baker D, James NH, Ratcliffe K, Jenkins M, Ashton SE, Sproat G, Swann R, Gray N, Ryan A, Jürgensmeier JM, Womack C. Smith NR, et al. Clin Cancer Res. 2010 Jul 15;16(14):3548-61. doi: 10.1158/1078-0432.CCR-09-2797. Epub 2010 Jul 6. Clin Cancer Res. 2010. PMID: 20606037

3

Discovery of AZD2932, a new Quinazoline Ether Inhibitor with high affinity for VEGFR-2 and PDGFR tyrosine kinases.

Plé PA, Jung F, Ashton S, Hennequin L, Laine R, Morgentin R, Pasquet G, Taylor S. Plé PA, et al. Among authors: ashton s. Bioorg Med Chem Lett. 2012 Jan 1;22(1):262-6. doi: 10.1016/j.bmcl.2011.11.019. Epub 2011 Nov 12. Bioorg Med Chem Lett. 2012. PMID: 22153662

4

Optimizing Therapeutic Effect of Aurora B Inhibition in Acute Myeloid Leukemia with AZD2811 Nanoparticles.

Floc'h N, Ashton S, Taylor P, Trueman D, Harris E, Odedra R, Maratea K, Derbyshire N, Caddy J, Jacobs VN, Hattersley M, Wen S, Curtis NJ, Pilling JE, Pease EJ, Barry ST. Floc'h N, et al. Among authors: ashton s. Mol Cancer Ther. 2017 Jun;16(6):1031-1040. doi: 10.1158/1535-7163.MCT-16-0580. Epub 2017 Mar 14. Mol Cancer Ther. 2017. PMID: 28292940

5

Modeling Dose and Schedule Effects of AZD2811 Nanoparticles Targeting Aurora B Kinase for Treatment of Diffuse Large B-cell Lymphoma.

Floc'h N, Ashton S, Ferguson D, Taylor P, Carnevalli LS, Hughes AM, Harris E, Hattersley M, Wen S, Curtis NJ, Pilling JE, Young LA, Maratea K, Pease EJ, Barry ST. Floc'h N, et al. Among authors: ashton s. Mol Cancer Ther. 2019 May;18(5):909-919. doi: 10.1158/1535-7163.MCT-18-0577. Epub 2019 Mar 14. Mol Cancer Ther. 2019. PMID: 30872381

6

PDGFR Inhibition Results in Pericyte Depletion and Hemorrhage into the Corpus Luteum of the Rat Ovary.

Hall AP, Ashton S, Horner J, Wilson Z, Reens J, Richmond GH, Barry ST, Wedge SR. Hall AP, et al. Among authors: ashton s. Toxicol Pathol. 2016 Jan;44(1):98-111. doi: 10.1177/0192623315613452. Epub 2015 Nov 3. Toxicol Pathol. 2016. PMID: 26534939

7

Expression of stromal genes associated with the angiogenic response are not differentiated between human tumour xenografts with divergent vascular morphologies.

Farren M, Weston S, Brown H, Broadbent N, Powell S, Shaw R, Smith NR, Inglis R, Graham A, Ashton S, Wedge SR, Barry ST. Farren M, et al. Among authors: ashton s. Angiogenesis. 2012 Dec;15(4):555-68. doi: 10.1007/s10456-012-9280-2. Epub 2012 May 27. Angiogenesis. 2012. PMID: 22644562

8

Discovery of new quinoline ether inhibitors with high affinity and selectivity for PDGFR tyrosine kinases.

Plé PA, Jung F, Ashton S, Hennequin L, Laine R, Lambert-van der Brempt C, Morgentin R, Pasquet G, Taylor S. Plé PA, et al. Among authors: ashton s. Bioorg Med Chem Lett. 2012 May 1;22(9):3050-5. doi: 10.1016/j.bmcl.2012.03.074. Epub 2012 Mar 28. Bioorg Med Chem Lett. 2012. PMID: 22497760

9

Inhibition of neutrophil infiltration into A549 lung tumors in vitro and in vivo using a CXCR2-specific antagonist is associated with reduced tumor growth.

Tazzyman S, Barry ST, Ashton S, Wood P, Blakey D, Lewis CE, Murdoch C. Tazzyman S, et al. Among authors: ashton s. Int J Cancer. 2011 Aug 15;129(4):847-58. doi: 10.1002/ijc.25987. Epub 2011 Apr 13. Int J Cancer. 2011. PMID: 21328342

10

Irreversible Inhibition of EGFR: Modeling the Combined Pharmacokinetic-Pharmacodynamic Relationship of Osimertinib and Its Active Metabolite AZ5104.

Yates JW, Ashton S, Cross D, Mellor MJ, Powell SJ, Ballard P. Yates JW, et al. Among authors: ashton s. Mol Cancer Ther. 2016 Oct;15(10):2378-2387. doi: 10.1158/1535-7163.MCT-16-0142. Epub 2016 Jul 20. Mol Cancer Ther. 2016. PMID: 27439477

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

145 results

Search Page

Filters